Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4402 - A Randomized Phase II study comparing cabazitaxel/prednisone to cabazitaxel alone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer (mCRPC): CABACARE

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Prostate Cancer

Presenters

Carlo Buonerba

Citation

Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370

Authors

C. Buonerba1, D. Bosso2, S. De Placido3, G. Di Lorenzo3

Author affiliations

  • 1 Medical Oncology Unit, Federico II Hospital, 80131 - Napoli/IT
  • 2 Department Of Clinical Medicine And Surgery, University Federico II of Naples, 80131 - Napoli/IT
  • 3 Medical Oncology Unit, Federico II Hospital, Napoli/IT
More

Resources

Abstract 4402

Background

In theTROPIC study, cabazitaxel (CAB), administered with prednisone (PDN) 10 mg daily, showed significant advantage in OS and PFS in patients (pts) progressing during or after docetaxel (DOC) treatment. Similar to DOC, CAB has been approved in combination with daily PDN, although the contributing role of PDN to efficacy and safety has been poorly investigated. Corticosteroids have a variety of effects, which may be either favourable, mediated by adrenal androgen and cytokine suppression, or detrimental, because of adverse events associated with long-term use, promiscuous activation of AR, immunosuppression, activation of AR variants highly sensitive to PDN even at low concentrations. Moreover PDN acts as a CYP3A4 inducer, affecting clearance of taxanes. It has been shown that AR point mutations are rare in therapy-naive pts but occur in 15-45% of CRPC pts and can increase AR affinity for a wide range of steroids. Over 100 mutations have been described. In the CHAARTED trial DOC was safely administered without daily PDN showing important clinical benefits in OS, PFS, and time to CRPC.; Safety data for CAB without PDN are lacking. AR-V7 positivity and RB loss/inactivation have been identified as potentially implicated in progression with next-generation targeted agents. We also would like to prospectively assess their role as predictive biomarkers of CAB activity.

Trial design

CABACARE is a randomized, phase II, open label, multicenter study comparing CAB at 25 mg/m2 q21 plus daily PDN (10 mg) vs CAB at 25 mg/m2 q21 alone in mCRPC pts progressed during or after DOC treatment. The study is designed to test non-inferiority in terms of PFS, according to PCWG-2, of CAB alone vs CAB plus PDN, assuming that the two arms are equally effective. Each arm will enroll 110 pts. Main secondary objectives are: safety, QoL, pain assessment, overall response rate (ORR), PSA response, time to PSA progression, time to radiological progression; OS; and time to skeletal related events (SRE). The influence of Arv7 and RB status on CAB activity will also be evaluated

Clinical trial identification

EUDRACT 2016- 005251-25

Legal entity responsible for the study

Consorzio Oncotech

Funding

Sanofi-Aventis

Disclosure

C. Buonerba: Consultant for Sanofi. Research support to institution from Sanofi, Astellas, Quercegen Pharmaceuticals. Travel expenses from Janssen-Cilag. S. De Placido: Research Support to Institution from Sanofi, Astellas, Quercegen Pharmaceuticals. G. Di Lorenzo: Consultant for Sanofi. Research Support to Institution from Sanofi, Astellas, Quercegen Pharmaceuticals.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.